The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jun 2013
Multicenter StudyCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor. ⋯ Chugai Pharmaceutical Co, Ltd.